Who is sponsoring NCT02607748?

NCT02607748 is sponsored by Cedars-Sinai Medical Center.

What drugs are being tested in NCT02607748?

Interventions in NCT02607748: 18F-NaF PET and coronary CTA imaging.

What condition does NCT02607748 study?

NCT02607748 studies Coronary Artery Disease, Atherosclerotic Plaque.

Is NCT02607748 still recruiting?

NCT02607748 is currently completed. Last updated 22 July 2022.

Last reviewed 2022-07-22 · How we verify

NCT02607748

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18F-fluoride (18F-NaF) PET for Identifying Coronary Atherosclerotic Plaques

Completed Phase 4 Last updated 22 July 2022

What this trial tests

Phase 4 trial testing 18F-NaF PET and coronary CTA imaging in Coronary Artery Disease in 41 participants. Completed in 31 August 2021.

Timeline

13 November 2015

Primary endpoint
31 August 2021

31 August 2021

Quick facts

Lead sponsor	Cedars-Sinai Medical Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	41
Start date	13 November 2015
Primary completion	31 August 2021
Estimated completion	31 August 2021
Sites	1 location across United States

Drugs / interventions tested

18F-NaF PET and coronary CTA imaging

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Atherosclerotic Plaque — all drugs for Atherosclerotic Plaque →

Sponsor

Cedars-Sinai Medical Center

Who can join

18 and older, any sex, with Coronary Artery Disease or Atherosclerotic Plaque. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate whether 18F-NaF (sodium fluoride) Positron Emission Tomography (PET) scans can be used to identify ruptured and high-risk plaque as compared to non-invasive coronary Computed Tomography Angiography (CTA) scans and high-definition intravascular ultrasound (IVUS). In subsets of patients, 18F-NaF PET scans and CCTA will be repeated to assess scan-rescan reproducibility.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Coronary 18F-Sodium Fluoride Uptake Predicts Outcomes in Patients With Coronary Artery Disease.
Kwiecinski J, Tzolos E, Adamson PD, Cadet S, et al · · 2020 · cited 125× · PMID 32553260 · DOI 10.1016/j.jacc.2020.04.046
Machine Learning with 18F-Sodium Fluoride PET and Quantitative Plaque Analysis on CT Angiography for the Future Risk of Myocardial Infarction.
Kwiecinski J, Tzolos E, Meah MN, Cadet S, et al · · 2022 · cited 47× · PMID 33893193 · DOI 10.2967/jnumed.121.262283
Bypass Grafting and Native Coronary Artery Disease Activity.
Kwiecinski J, Tzolos E, Fletcher AJ, Nash J, et al · · 2022 · cited 38× · PMID 35216930 · DOI 10.1016/j.jcmg.2021.11.030
Latent Coronary Plaque Morphology From Computed Tomography Angiography, Molecular Disease Activity on Positron Emission Tomography, and Clinical Outcomes.
Kwiecinski J, Kolossváry M, Tzolos E, Meah MN, et al · · 2023 · cited 11× · PMID 37165878 · DOI 10.1161/atvbaha.123.319332
Sex differences in coronary atherosclerotic plaque activity using 18F-sodium fluoride positron emission tomography.
Kwiecinski J, Wang KL, Tzolos E, Moss A, et al · · 2024 · cited 6× · PMID 38926161 · DOI 10.1007/s00259-024-06810-x

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Cedars-Sinai Medical Center trials

Trials by the same sponsor.

NCT06012487 — Correlates and Control of Blood Pressure Variability · Phase 1 · not yet recruiting
NCT07495995 — SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis · Phase 2 · not yet recruiting
NCT07413965 — TAVR vs SAVR in Severe Bicuspid Aortic Stenosis · NA · not yet recruiting
NCT06521021 — CHOICE to AVOID or RESIST · NA · not yet recruiting
NCT07499089 — Together-Breast Cancer Support Platform · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02607748 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cedars-Sinai Medical Center
Last refreshed: 22 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02607748.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing